Regulatory Approvals - Tianda Pharmaceuticals received drug registration approval for "Nicorandil for Injection" from the National Medical Products Administration of China[15]. - Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. obtained drug registration approval for "Ibuprofen suspension" from the National Medical Products Administration of China[16]. - In 2024, the Group has received drug registration approvals for 4 new varieties, including pediatric drugs and a cardiocerebrovascular drug, which are expected to drive new growth momentum[75]. Corporate Social Responsibility - Tianda Pharmaceuticals was awarded the "Caring Company" logo for the fourth consecutive year by the Hong Kong Council of Social Service[13]. - Tianda Pharmaceuticals was recognized as a "Happy Company" under the "Happiness-at-Work Promotional Scheme" by the Promoting Happiness Index Foundation[12]. - The Group has conducted over 40 charity clinic sessions and organized numerous TCM-themed activities to promote TCM knowledge in the community[68]. Business Operations and Strategy - The company operates multiple TDMall locations, including in Jordan and Causeway Bay, enhancing its market presence[20][21]. - The Group's strategy includes the "Three Developments" focusing on Chinese medicine, innovative drugs, and quality healthcare services, aiming to consolidate core products and expand sales channels[39][42]. - The Group plans to launch three new products in 2025, enhancing its product pipeline and focusing on R&D for innovative drugs and consumer healthcare products[40][43]. - The Group opened its sixth TDMall globally and fifth in the Greater Bay Area in October 2024, aiming to establish it as an oncology treatment center[45]. - The Group aims to promote a collaborative development model of "drugs + medical services" to enhance the quality of the Chinese medicine business[46]. Financial Performance - The Group's total revenue for the Year was HK$329.9 million, a significant decline from HK$532.1 million in the Previous Financial Year, resulting in increased losses attributable to shareholders from HK$24.2 million to HK$61.4 million[52]. - Revenue from the Pharmaceuticals and medical technologies business was HK$283.9 million, down 39.7% from HK$470.7 million in the Previous Financial Year, primarily due to decreased demand for Tuoen® Ibuprofen and competitive pricing strategies affecting Tuoping® Valsartan capsules[82]. - The loss attributable to shareholders increased from HK$24.2 million to HK$61.4 million, reflecting the overall decline in business performance[89]. Governance and Management - The Company emphasizes corporate governance with various committees including Audit, Remuneration, and Risk Management[5]. - The Company has complied with the Corporate Governance Code during the year, except for the separation of the roles of Chairman and CEO[104]. - The Board consists of 6 male Directors and 1 female Director, including 2 Executive Directors and 3 Independent Non-executive Directors[110]. - The Company has established various committees, including the audit, nomination, remuneration, and risk management committees, primarily composed of INEDs[133]. - The Board has developed and reviewed policies related to Board diversity and shareholder communication[126]. Research and Development - The Group's R&D projects include one Class 1 TCM innovative drug, three Class 3 TCM new drugs, and twelve chemical generic drugs, indicating a rich R&D pipeline[74]. - The Group is focusing on the R&D of traditional Chinese medicine, aiming for stronger R&D, larger markets, and enhanced efficacy through technological advancements and resource growth[64]. - The Group is advancing the Phase II clinical trials of a Class 1 TCM innovative drug for chronic heart failure, highlighting its commitment to innovative medicine[76]. Market Challenges and Outlook - In 2024, the pharmaceutical market faced challenges due to economic uncertainty, with a focus on respiratory infection and antihypertensive drugs struggling to grow as inventory clearance continued post-pandemic[39][42]. - The Chinese medicine segment faced a decline in end-user demand due to the economic environment, impacting trading and production of Chinese medicinal materials[41][43]. - Future market demand is expected to improve as the economy recovers and national policies supporting the pharmaceutical industry are enhanced[46]. Human Resources - As of December 31, 2024, the Group employed approximately 701 employees across Hong Kong, the PRC, and Australia[99]. - The board currently consists of 6 male and 1 female directors, with female representation at approximately 48% at the workforce level[155].
天大药业(00455) - 2025 - 年度财报